DSpace Repository

Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models.

Show simple item record

dc.contributor.author Choque-Guevara, Ricardo
dc.contributor.author Poma-Acevedo, Astrid
dc.contributor.author Montesinos-Millan, Ricardo
dc.contributor.author Rios-Matos, Dora
dc.contributor.author Gutierrez-Manchay, Kristel
dc.contributor.author Montalvan-Avalos, Angela
dc.contributor.author Quinones-Garcia, Stefany
dc.contributor.author Cauti-Mendoza, Maria de Grecia
dc.contributor.author Agurto-Arteaga, Andres
dc.contributor.author Ramirez-Ortiz, Ingrid
dc.contributor.author Criollo-Orozco, Manuel
dc.contributor.author Huaccachi-Gonzales, Edison
dc.contributor.author Romero, Yomara K.
dc.contributor.author Perez-Martinez, Norma
dc.contributor.author Isasi-Rivas, Gisela
dc.contributor.author Sernaque-Aguilar, Yacory
dc.contributor.author Villanueva-Perez, Doris
dc.contributor.author Ygnacio, Freddy
dc.contributor.author Vallejos-Sanchez, Katherine
dc.contributor.author Fernandez-Sanchez, Manolo
dc.contributor.author Guevara-Sarmiento, Luis A.
dc.contributor.author Fernandez-Diaz, Manolo
dc.contributor.author Zimic-Peralta, Mirko Juan
dc.contributor.author COVID-19 Working Group in Peru
dc.date.accessioned 2022-09-09T18:52:23Z
dc.date.available 2022-09-09T18:52:23Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/12167
dc.description.abstract COVID-19 pandemic has accelerated the development of vaccines against its etiologic agent, SARS-CoV-2. However, the emergence of new variants of the virus lead to the generation of new alternatives to improve the current sub-unit vaccines in development. In the present report, the immunogenicity of the Spike RBD of SARS-CoV-2 formulated with an oil-in-water emulsion and a water-in-oil emulsion with squalene was evaluated in mice and hamsters. The RBD protein was expressed in insect cells and purified by chromatography until >95% purity. The protein was shown to have the appropriate folding as determined by ELISA and flow cytometry binding assays to its receptor, as well as by its detection by hamster immune anti-S1 sera under non-reducing conditions. In immunization assays, although the cellular immune response elicited by both adjuvants were similar, the formulation based in water-in-oil emulsion and squalene generated an earlier humoral response as determined by ELISA. Similarly, this formulation was able to stimulate neutralizing antibodies in hamsters. The vaccine candidate was shown to be safe, as demonstrated by the histopathological analysis in lungs, liver and kidney. These results have shown the potential of this formulation vaccine to be evaluated in a challenge against SARS-CoV-2 and determine its ability to confer protection. en_US
dc.language.iso eng
dc.publisher Public Library of Science
dc.relation.ispartofseries PLoS ONE
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Immunologic adjuvants en_US
dc.subject Enzyme-linked immunoassays en_US
dc.subject Antibodies en_US
dc.subject Hamsters en_US
dc.subject SARS CoV 2 en_US
dc.subject Immune response en_US
dc.subject Milk en_US
dc.subject Cell binding en_US
dc.title Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models. en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1371/journal.pone.0269823
dc.relation.issn 1932-6203


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics